Details of Disease

General Information of Disease (ID: DISMLRZY)

• Disease Name: Bronchioalveolar carcinoma
• Synonyms: stage 0 adenosquamous lung carcinoma aJCC v7; stage 0 adenosquamous lung carcinoma aJCC v6 and v7; stage 0 adenosquamous lung carcinoma aJCC v6; stage 0 adenosquamous lung cancer; stage 0 adenosquamous cell lung carcinoma; stage 0 adenosquamous cell carcinoma of the lung; stage 0 adenosquamous cell carcinoma of lung; lung adenosquamous cell carcinoma in situ; in situ pulmonary adenocarcinoma; bronchioalveolar carcinoma; adenosquamous cell carcinoma in situ of the lung; adenosquamous cell carcinoma in situ of lung; bronchioloalveolar carcinoma; lung adenocarcinoma In situ
• Disease Class: 2C25: Lung cancer
• Definition: A localized non-invasive adenocarcinoma of the lung measuring 3 cm or less. It is characterized by a pure lepidic growth pattern and the lack of stromal, vascular, or pleural invasion.|Editor note: check why NCIT has two classes
• Disease Hierarchy:
  DISSTE29: Adenocarcinoma in situ
  DISF35KU: Lung carcinoma in situ
  DISD51WR: Lung adenocarcinoma
  DISMLRZY: Bronchioalveolar carcinoma
• ICD Code:
  ICD-11: ICD-11: 2C25.0
  ICD-9: ICD-9: 162
  Expand ICD-9: 162
• Disease Identifiers:
  MONDO ID: MONDO_0000503
  UMLS CUI: C4521520
  MedGen ID: 1620128

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[1]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IBI-308	DM5KL8E	Phase 3	Monoclonal antibody	[1]
INCSHR1210	DMZA2K0	Phase 3	Monoclonal antibody	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CLDN10	OT2CVAKY	Strong	Altered Expression	[2]

References

• [1] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [2] Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma.J Cardiothorac Surg. 2013 Apr 16;8:95. doi: 10.1186/1749-8090-8-95.